Figure 2.
(A) At the 18-month follow up [1-NA], (B) the patients with KRAS-mutated ctDNA had a median PFS of 3 months (1–6 months, 95%CI 0.8–3.6), contrary to those with no detection of KRAS ctDNA whose PFS had not yet been reached (p < 0.001).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.